CardieX Limited provided revenue guidance for the fiscal year 2023. At this stage group revenue for fiscal year 2023 is expected to be more than 7% up on the revenues achieved in fiscal year 2022 excluding any potential acceleration of Clinichain revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.054 AUD | +1.89% | -8.47% | -60.00% |
Apr. 02 | Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes | MT |
Apr. 02 | Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5% | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-60.00% | 10.5M | |
+7.84% | 218B | |
+7.35% | 184B | |
+13.04% | 135B | |
+26.03% | 107B | |
-1.33% | 62.38B | |
+11.80% | 51.37B | |
+4.81% | 50.9B | |
+0.30% | 40.87B | |
+2.78% | 36.28B |
- Stock Market
- Equities
- CDX Stock
- News CardieX Limited
- CardieX Limited Provides Revenue Guidance for the Fiscal Year 2023